Mylotarg is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. The primary component is Gemtuzumab Ozogamicin.
Product ID | 0008-4510_091bfc51-844b-478e-8628-10c00ef7c5b8 |
NDC | 0008-4510 |
Product Type | Human Prescription Drug |
Proprietary Name | Mylotarg |
Generic Name | Gemtuzumab Ozogamicin |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-09-07 |
Marketing Category | BLA / BLA |
Application Number | BLA761060 |
Labeler Name | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
Substance Name | GEMTUZUMAB OZOGAMICIN |
Active Ingredient Strength | 5 mg/5mL |
Pharm Classes | CD33-directed Immunoconjugate [EPC],CD33-directed Antibody Interactions [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2017-09-07 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761060 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-09-07 |
Ingredient | Strength |
---|---|
GEMTUZUMAB OZOGAMICIN | 5 mg/5mL |
SPL SET ID: | 32fd2bb2-1cfa-4250-feb8-d7956c794e05 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MYLOTARG 88707380 not registered Live/Pending |
Pfizer Inc. 2019-11-26 |
MYLOTARG 88707320 not registered Live/Pending |
Pfizer Inc. 2019-11-26 |
MYLOTARG 88397804 not registered Live/Pending |
Wyeth LLC 2019-04-23 |
MYLOTARG 86964864 not registered Dead/Abandoned |
Wyeth LLC 2016-04-05 |
MYLOTARG 86391721 5530468 Live/Registered |
Wyeth LLC 2014-09-11 |
MYLOTARG 85440982 not registered Dead/Abandoned |
Wyeth LLC 2011-10-06 |
MYLOTARG 75491539 2443040 Dead/Cancelled |
WYETH LLC 1998-05-26 |